Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 113
Filter
1.
Article in English | MEDLINE | ID: mdl-35616250

ABSTRACT

Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease associated with loss of upper and lower motor neurones. It leads to death by respiratory failure and has a typical prognosis of 2-3 years. The immune system has been shown to play a role in the pathophysiology of ALS. Some of the most important immune genes are within the human leukocyte antigen (HLA) region, and a recent genome-wide association study (GWAS) has identified a risk allele for ALS within the HLA region. Older studies have also suggested an HLA association with ALS, with certain HLA alleles showing differing expression between patients and controls. This systematic review and meta-analysis examines the previous studies performed in this field.Methods: We used established publication search engines. Findings were excluded if they did not meet the selection criteria. We then undertook statistical meta-analysis on the eligible papers, using a fixed effects model.Results: There were eight eligible papers. There were three statistically significant meta-analysis findings, although these would not be significant after correction for multiple comparisons. The frequencies of HLA-A9 and HLA-DR4 genotypes were lower in ALS subjects than controls, and HLA-B35 was higher in ALS subjects.Discussion: This systematic review and meta-analysis do not confirm all the previously reported associations of HLA with ALS, but shows three alleles of interest. However, there are limitations to the studies, which include the use of older serotyping methodology and the small numbers of subjects. Given the recent GWAS association with HLA, further modern HLA studies are warranted.


Subject(s)
Amyotrophic Lateral Sclerosis , Neurodegenerative Diseases , Humans , Amyotrophic Lateral Sclerosis/genetics , Genome-Wide Association Study , HLA Antigens , Motor Neurons
2.
J Contam Hydrol ; 248: 104027, 2022 06.
Article in English | MEDLINE | ID: mdl-35640423

ABSTRACT

We present the results of a lab-scaled feasibility study to assess the performance of electrical resistivity tomography for detection, characterization, and monitoring of fuel grade ethanol releases to the subsurface. Further, we attempt to determine the concentration distribution of the ethanol from the electrical resistivity tomography data using mixing-models. Ethanol is a renewable fuel source as well as an oxygenate fuel additive currently used to replace the known carcinogen methyl tert-butyl ether; however, ethanol is preferentially biodegraded and a cosolvent. When introduced to areas previously impacted by nonethanol-based fuels, it will facilitate the persistence of carcinogenic fuel compounds like benzene and ethylbenzene, as well as remobilize them to the ground water. These compounds would otherwise be retained in the soil column undergoing active or passive remediation processes such as soil vapor extraction or natural attenuation. Here, we introduce ethanol to a saturated Ottawa sand in a tank instrumented for four-dimensional geoelectrical measurements. Forward model results suggest pure phase ethanol released into a water saturated silica sand should present a detectable target for electrical resistivity tomography relative to a saturated silica sand only. We observe the introduction of ethanol to the closed hydraulic system and subsequent migration over the duration of the experiment. One-dimensional and three-dimensional temporal data are assessed for the detection, characterization, and monitoring of the ethanol release. Results suggest one-dimensional geoelectrical measurements may be useful for monitoring a release, while three-dimensional geoelectrical field imaging would be useful to characterize, monitor, and design effective remediation approaches for an ethanol release, assuming field conditions do not preclude the application of geoelectrical methods. We then attempt to use predictive mixing models to calculate the distribution of ethanol concentration within the measurement domain. For this study we examine four different models: a nested parallel mixing model, a nested cubic mixing model, the complex refractive index model (CRIM), and the Lichtenecker-Rother (L-R) model. The L-R model, modified to include an electrical formation factor geometry term, provided the best agreement with expected EtOH concentrations.


Subject(s)
Biofuels , Water Pollutants, Chemical , Environmental Monitoring/methods , Ethanol , Sand , Silicon Dioxide , Soil , Water Pollutants, Chemical/analysis
3.
Article in English | MEDLINE | ID: mdl-34396845

ABSTRACT

Objective: To investigate changes in immune markers and frequencies throughout disease progression in patients with amyotrophic lateral sclerosis (ALS). Methods: In this longitudinal study, serial blood samples were collected from 21 patients with ALS over a time period of up to 16 months. Flow cytometry was used to quantitate CD14, HLA-DR, and CD16 marker expression on monocyte subpopulations and neutrophils, as well as their cell population frequencies. A Generalized Estimating Equation model was used to assess the association between changes in these immune parameters and disease duration and the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Results: CD14 expression on monocyte subpopulations increased with both disease duration and a decrease in ALSFRS-R score in patients with ALS. HLA-DR expression on monocyte subpopulations also increased with disease severity and/or duration. The expression of CD16 did not change relative to disease duration or ALSFRS-R. Finally, patients had a reduction in non-classical monocytes and an increase in the classical to non-classical monocyte ratio throughout disease duration. Conclusion: The progressive immunological changes observed in this study provide further support that monocytes are implicated in ALS pathology. Monocytic CD14 and HLA-DR surface proteins may serve as a therapeutic target or criteria for the recruitment of patients with ALS into clinical trials for immunomodulatory therapies.


Subject(s)
Amyotrophic Lateral Sclerosis , HLA-DR Antigens , Lipopolysaccharide Receptors , Monocytes , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Biomarkers/metabolism , Flow Cytometry , HLA-DR Antigens/metabolism , Humans , Lipopolysaccharide Receptors/metabolism , Longitudinal Studies , Monocytes/metabolism
4.
Expert Rev Neurother ; 17(6): 561-577, 2017 06.
Article in English | MEDLINE | ID: mdl-27983884

ABSTRACT

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease defined by the presence of muscle weakness. The motor features of disease are heterogeneous in site of onset and progression. There are also extra-motor features in some patients. The genetic basis for extra-motor features is uncertain. The heterogeneity of ALS is an issue for clinical trials. Areas covered: This paper reviews the range and prevalence of extra-motor features associated with ALS, and highlights the current information about genetic associations with extra-motor features. Expert commentary: There are extra-motor features of ALS, but these are not found in all patients. The most common is cognitive abnormality. More data is required to ascertain whether extra-motor features arise with progression of disease. Extra-motor features are reported in patients with a range of causative genetic mutations, but are not found in all patients with these mutations. Further studies are required of the heterogeneity of ALS, and genotype/phenotype correlations are required, taking note of extra-motor features.


Subject(s)
Amyotrophic Lateral Sclerosis , Mutation , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/physiopathology , Disease Progression , Humans
5.
J Neurol Neurosurg Psychiatry ; 87(8): 821-30, 2016 08.
Article in English | MEDLINE | ID: mdl-27093948

ABSTRACT

While the past 2 decades have witnessed an increasing understanding of amyotrophic lateral sclerosis (ALS) arising from East Asia, particularly Japan, South Korea, Taiwan and China, knowledge of ALS throughout the whole of Asia remains limited. Asia represents >50% of the world population, making it host to the largest patient cohort of ALS. Furthermore, Asia represents a diverse population in terms of ethnic, social and cultural backgrounds. In this review, an overview is presented that covers what is currently known of ALS in Asia from basic epidemiology and genetic influences, through to disease characteristics including atypical phenotypes which manifest a predilection for Asians. With the recent establishment of the Pan-Asian Consortium for Treatment and Research in ALS to facilitate collaborations between clinicians and researchers across the region, it is anticipated that Asia and the Pacific will contribute to unravelling the uncertainties in ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/complications , Amyotrophic Lateral Sclerosis/epidemiology , Motor Neuron Disease/complications , Motor Neuron Disease/epidemiology , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/mortality , Asia/epidemiology , Disease Progression , Humans , Motor Neuron Disease/genetics , Motor Neuron Disease/mortality , Phenotype , Syndrome
8.
J Neurol Sci ; 357(1-2): 22-7, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26198021

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the loss of upper cortical and lower motor neurons. ALS causes death within 2-5years of diagnosis. Diet and body mass index influence the clinical course of disease, however there is limited information about the expression of metabolic proteins and fat-derived cytokines (adipokines) in ALS. In healthy controls and subjects with ALS, we have measured levels of proteins and adipokines that influence metabolism. We find altered levels of active ghrelin, gastric inhibitory peptide (GIP), pancreatic polypeptide (PP), lipocalin-2, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6) and 8 (IL-8), and tumor necrosis factor alpha (TNFα) in the plasma of ALS patients relative to controls. We also observe a positive correlation between the expression of plasma nerve growth factor (NGF) relative to disease duration, and an inverse correlation between plasma glucagon and the ALS functional rating scale-revised (ALSFRS-R). Further studies are required to determine whether altered expression of metabolic proteins and adipokines contribute to motor neuron vulnerability and how these factors act to modify the course of disease.


Subject(s)
Adipokines/blood , Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/metabolism , Blood Proteins/metabolism , Gene Expression Profiling , Metabolism , Acute-Phase Proteins , Body Mass Index , Case-Control Studies , Female , Gastric Inhibitory Polypeptide/blood , Ghrelin/blood , Glucagon/blood , Humans , Interleukin-6/blood , Interleukin-8/blood , Lipocalin-2 , Lipocalins/blood , Male , Middle Aged , Nerve Growth Factor/blood , Pancreatic Polypeptide/blood , Plasminogen Activator Inhibitor 1/blood , Proto-Oncogene Proteins/blood , Severity of Illness Index , Tumor Necrosis Factor-alpha/blood
9.
J Neurol Sci ; 353(1-2): 122-9, 2015.
Article in English | MEDLINE | ID: mdl-25958264

ABSTRACT

There is a need for a blood biomarker of disease activity in ALS. This marker needs to measure the loss of motor neurones. Phosphorylated neurofilament heavy chain (pNfH) in the serum is a biomarker of axonal injury. Previous studies have found that levels of pNfH are elevated in ALS. We have performed a serial study of pNfH levels in 98 subjects from our ALS clinic. There was significant elevation of levels of pNfH in subjects with ALS compared to controls, although there was considerable variability. In studies of individuals who had two or more serial samples, we found that the levels of pNfH increased over time in the early stage of disease. Levels were low in subjects with long survival. The rate of rise of pNfH was inversely correlated with survival. We suggest that the initial level of pNfH is a marker of disease severity and that changes in pNfH levels are markers of disease progression.


Subject(s)
Amyotrophic Lateral Sclerosis/blood , Neurofilament Proteins/blood , Adult , Aged , Aged, 80 and over , Amyotrophic Lateral Sclerosis/mortality , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Linear Models , Male , Middle Aged , Phosphorylation , Young Adult
10.
J Neuroimmunol ; 276(1-2): 213-8, 2014 Nov 15.
Article in English | MEDLINE | ID: mdl-25262158

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized by the progressive loss of motor neurons within the central nervous system. Neural degeneration and inflammatory processes, including activation of the complement system are hallmarks of this pathology. Our past work in ALS animal models (hSOD1 G93A rodents) has revealed that blockade of the receptor for complement activation fragment C5a (C5aR), improves ALS-like symptoms and extends survival. We now show that the levels of C5a and C5b-9, but not C3a nor C4a, are significantly elevated in plasma from ALS patients compared to healthy controls. C5a was also elevated within leukocytes from ALS patients suggesting heightened C5a receptor interaction. Overall, these findings indicate that there is enhanced peripheral immune complement terminal pathway activation in ALS, which may have relevance in the disease process.


Subject(s)
Amyotrophic Lateral Sclerosis/blood , Complement C5a/metabolism , Complement Membrane Attack Complex/metabolism , Adult , Aged , Amyotrophic Lateral Sclerosis/pathology , Anaphylatoxins/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression Regulation , Humans , Leukocytes/metabolism , Male , Middle Aged , Statistics, Nonparametric
11.
J Neuroimmunol ; 249(1-2): 93-5, 2012 Aug 15.
Article in English | MEDLINE | ID: mdl-22633272

ABSTRACT

Interleukin 33 (IL-33) is a cytokine that functions as an alarmin and is released from damaged tissue. The receptor for IL-33 is ST2, which exists as membrane bound and soluble forms. Levels of IL-33 and soluble ST2 (sST2) are elevated in some inflammatory diseases. Amyotrophic lateral sclerosis (ALS) is a disease that is due to loss of motor neurones, with some neuro-inflammation at the site of pathology. This study was performed to measure levels of IL-33 and sST2 in ALS. Serum was obtained from subjects with ALS (n=42) and healthy controls (n=38). Levels of IL-33 and s ST2 were measured with ELISA. The level of Il-33 was significantly lower in ALS subjects than healthy controls, and the levels of sST2 were significantly higher. The lower levels of IL-33 could be due to degradation of IL-33 by caspases released from apoptotic cells. However the levels of IL-33 could also be lower due to effects of sST2 which acts as a receptor for IL-33. The levels of sST2 could reflect inflammation in ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/immunology , Interleukins/blood , Receptors, Cell Surface/blood , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33 , Interleukins/immunology , Male , Middle Aged , Receptors, Cell Surface/immunology
12.
Clin Neurophysiol ; 123(12): 2446-53, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22608482

ABSTRACT

OBJECTIVES: To evaluate differences among patients with different clinical features of ALS, we used our Bayesian method of motor unit number estimation (MUNE). METHODS: We performed serial MUNE studies on 42 subjects who fulfilled the diagnostic criteria for ALS during the course of their illness. Subjects were classified into three subgroups according to whether they had typical ALS (with upper and lower motor neurone signs) or had predominantly upper motor neurone weakness with only minor LMN signs, or predominantly lower motor neurone weakness with only minor UMN signs. In all subjects we calculated the half life of MUs, defined as the expected time for the number of MUs to halve, in one or more of the abductor digiti minimi (ADM), abductor pollicis brevis (APB) and extensor digitorum brevis (EDB) muscles. RESULTS: The mean half life of MUs was less in subjects who had typical ALS with both upper and lower motor neurone signs than in those with predominantly upper motor neurone weakness or predominantly lower motor neurone weakness. In 18 subjects we analysed the estimated size of the MUs and demonstrated the appearance of large MUs in subjects with upper or lower motor neurone predominant weakness. We found that the appearance of large MUs was correlated with the half life of MUs. CONCLUSIONS: Patients with different clinical features of ALS have different rates of loss and different sizes of MUs. SIGNIFICANCE: These findings could indicate differences in disease pathogenesis.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Bayes Theorem , Disease Progression , Motor Neurons/pathology , Nerve Degeneration/pathology , Adult , Aged , Amyotrophic Lateral Sclerosis/mortality , Amyotrophic Lateral Sclerosis/physiopathology , Cell Count , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Muscle, Skeletal/innervation , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Retrospective Studies , Survival Rate , Time Factors
13.
Clin Neurophysiol ; 123(10): 2092-8, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22520163

ABSTRACT

OBJECTIVE: To use our Bayesian method of motor unit number estimation (MUNE) to evaluate lower motor neuron degeneration in ALS. METHODS: In subjects with ALS we performed serial MUNE studies. We examined the repeatability of the test and then determined whether the loss of MUs was fitted by an exponential or Weibull distribution. RESULTS: The decline in motor unit (MU) numbers was well-fitted by an exponential decay curve. We calculated the half life of MUs in the abductor digiti minimi (ADM), abductor pollicis brevis (APB) and/or extensor digitorum brevis (EDB) muscles. The mean half life of the MUs of ADM muscle was greater than those of the APB or EDB muscles. The half-life of MUs was less in the ADM muscle of subjects with upper limb than in those with lower limb onset. CONCLUSIONS: The rate of loss of lower motor neurons in ALS is exponential, the motor units of the APB decay more quickly than those of the ADM muscle and the rate of loss of motor units is greater at the site of onset of disease. SIGNIFICANCE: This shows that the Bayesian MUNE method is useful in following the course and exploring the clinical features of ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Models, Theoretical , Motor Neurons/pathology , Nerve Degeneration/pathology , Adult , Aged , Bayes Theorem , Female , Humans , Male , Median Nerve/pathology , Middle Aged , Peroneal Nerve/pathology , Ulnar Nerve/pathology
14.
Clin Neurophysiol ; 123(10): 2080-91, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22521362

ABSTRACT

OBJECTIVE: To assess the relationship between Bayesian MUNE and histological motor neuron counts in wild-type mice and in an animal model of ALS. METHODS: We performed Bayesian MUNE paired with histological counts of motor neurons in the lumbar spinal cord of wild-type mice and transgenic SOD1(G93A) mice that show progressive weakness over time. We evaluated the number of acetylcholine endplates that were innervated by a presynaptic nerve. RESULTS: In wild-type mice, the motor unit number in the gastrocnemius muscle estimated by Bayesian MUNE was approximately half the number of motor neurons in the region of the spinal cord that contains the cell bodies of the motor neurons supplying the hindlimb crural flexor muscles. In SOD1(G93A) mice, motor neuron numbers declined over time. This was associated with motor endplate denervation at the end-stage of disease. CONCLUSION: The number of motor neurons in the spinal cord of wild-type mice is proportional to the number of motor units estimated by Bayesian MUNE. In SOD1(G93A) mice, there is a lower number of estimated motor units compared to the number of spinal cord motor neurons at the end-stage of disease, and this is associated with disruption of the neuromuscular junction. SIGNIFICANCE: Our finding that the Bayesian MUNE method gives estimates of motor unit numbers that are proportional to the numbers of motor neurons in the spinal cord supports the clinical use of Bayesian MUNE in monitoring motor unit loss in ALS patients.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Motor Neurons/pathology , Spinal Cord/pathology , Superoxide Dismutase/genetics , Animals , Bayes Theorem , Disease Models, Animal , Lumbar Vertebrae , Mice , Mice, Transgenic , Models, Theoretical , Neuromuscular Junction/pathology , Superoxide Dismutase-1
17.
Curr Mol Med ; 11(3): 246-54, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21375489

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disease. The cause is unknown, but genetic abnormalities have been identified in subjects with familial ALS and also in subjects with sporadic ALS. Environmental factors such as occupational exposure have been shown to be risk factors for the development of ALS. Patients differ in their clinical features and differ in the clinical course of disease. Immune abnormalities have been found in the central nervous system by pathological studies and also in the blood and CSF of subjects with ALS. Inflammation and immune abnormalities are also found in animals with a model of ALS due to mutations in the SOD1 gene. Previously it has been considered that immune abnormalities might contribute to the pathogenesis of disease. However more recently it has become apparent that an immune response can occur as a response to damage to the nervous system and this can be protective.


Subject(s)
Amyotrophic Lateral Sclerosis , Inflammation/immunology , Superoxide Dismutase/genetics , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/immunology , Amyotrophic Lateral Sclerosis/pathology , CD4-Positive T-Lymphocytes , Central Nervous System/immunology , Central Nervous System/injuries , Central Nervous System/pathology , Humans , Mutation , Occupational Exposure/adverse effects , Superoxide Dismutase-1
18.
J Neurol Sci ; 304(1-2): 117-21, 2011 May 15.
Article in English | MEDLINE | ID: mdl-21349546

ABSTRACT

For the study of stroke outcomes, there is the need for measurements of severity of stroke damage. Phosphorylated neurofilament heavy protein (pNfH) levels are elevated in axonal injury. We have measured levels of pNfH in stroke and correlated these levels with measures of stroke severity. Blood samples were collected from 54 ischaemic stroke patients at day 1, week 1 (days 7-10) and weeks 3-6, and an ELISA was used to measure pNfH levels in each patient at each time-point. Serum pNfH levels were significantly elevated in stroke patients compared to healthy controls. The levels were low at day 1, higher at day 7 and reached a peak at week 3, the latest day that we assessed. Significant associations were found between the pNfH levels at week 3 and early and stroke severity, size and outcome. Blood pNfH levels that reflect the severity of ischaemic stroke, are correlated with outcome and rise during the weeks after stroke. This may be a useful measure of tissue damage in stroke.


Subject(s)
Axons/metabolism , Brain Ischemia/blood , Neurofilament Proteins/blood , Severity of Illness Index , Stroke/blood , Aged , Aged, 80 and over , Biomarkers/blood , Biomarkers/metabolism , Brain Ischemia/metabolism , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neurofilament Proteins/metabolism , Phosphorylation/physiology , Stroke/metabolism
19.
Intern Med J ; 41(2): 199-202, 2011 Feb.
Article in English | MEDLINE | ID: mdl-22747555

ABSTRACT

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is a clinical syndrome associated with mitochondrial abnormalities. In approximately 80% of patients, the syndrome is associated with the A3243G mutation. However, it has been realized that the A3243G mutation is not uncommon in the general population and is found in many patients with clinical presentations other than MELAS. We present four patients who presented with rhabdomyolysis, muscle fatigue, external ophthalmoplegia and myoclonic jerks respectively. These patients were all found to have the A3243G mutation on muscle biopsy. These patients illustrate the variety of presentations associated with A3243G mutation.


Subject(s)
MELAS Syndrome/diagnosis , MELAS Syndrome/genetics , Mutation/genetics , Aged , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...